Recent Developments, Liquidity and Management’s Plans (Details Narrative) - USD ($)		3 Months Ended		12 Months Ended
	Apr. 16, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Mar. 23, 2020
Goodwill		$ 10,498,539		$ 10,498,539
Cash on hand		1,189,223		555,947
Marketable securities		7,998,891		11,003,071
Loss from operations		4,122,033	$ 3,089,703
Working capital		7,605,453
Stockholders' equity		19,622,141	(8,346,735)	23,647,174	$ (5,257,032)
Accumulated deficit		82,683,601		78,561,568
Net cash provided by operating activities		2,366,182	1,505,182
Net loss		4,122,033	3,089,703
Increase in trade and other payables		$ 1,431,487	$ 927,935
Contribution Agreement [Member] | Premas Biotech PVT Ltd [Member]
Amount owed on investments				1,500,000
Payments to investments				$ 1,200,000
Merger Agreement [Member]
Issuance of post reverse stock split	28,553,307
Exchange ratio percentage	77.05%
Percentage of common stock	49.68%
Merger Agreement [Member] | Pre-funded Warrants [Member]
Warrants to purchase	986,486
Cystron Biotech LLC [Member] | Membership Interest Purchase Agreement [Member]
Acquired membership interests, percentage						100.00%
MYMD Pharmaceuticals, Inc., [Member] | Merger Agreement [Member]
Business acquisition description	Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued 28,553,307 post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio. Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD Florida held approximately 77.05% of the Company’s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company’s net cash at closing. Holders of pre-Merger common stock of the Company held approximately 22.95% of the outstanding equity of the Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315 MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of the Merger
Akers Biosciences, Inc [Member]
Goodwill	$ 10,498,539
Pre market capitalization	42,477,346
Tangible asset	$ 31,978,807
Stock Issued During Period, Shares, Acquisitions	8,335,627
Akers Biosciences, Inc [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period	263,026
Share Price	$ 4.94